RXRX Q1 2024 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+11.2% YoY

Gross Profit

$2M17.2% margin

Operating Income

-$96M-714.1% margin

Net Income

-$91M-677.3% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+27.0%

Cash Flow

Operating Cash Flow

-$102M

Free Cash Flow

-$109M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$558M

Total Liabilities

$157M

Stockholders' Equity

$401M

Cash & Equivalents

$300M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$12M	+11.2%
Gross Profit	$2M	-$314,000	+840.4%
Operating Income	-$96M	-$70M	-37.9%
Net Income	-$91M	-$65M	-39.9%

Revenue Segments

License and Service

$13M98%

Grant

$303,0002%